Cargando…

Effect of Vortioxetine on Cognitive Impairment in Patients With Major Depressive Disorder: A Systematic Review and Meta-analysis of Randomized Controlled Trials

BACKGROUND: Dementia and depression are increasingly common worldwide, and their effective control could ease the burden on economies, public health systems, and support networks. Vortioxetine is a new antidepressant with multipharmacologic actions that elevate the concentration of serotonin and mod...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, I-Chen, Chang, Tsui-San, Chen, Chiehfeng, Sung, Jia-Ying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Regular Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743961/ https://www.ncbi.nlm.nih.gov/pubmed/35981958 http://dx.doi.org/10.1093/ijnp/pyac054

Ejemplares similares

The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials
por: McIntyre, RS, et al.
Publicado: (2016)

Randomized, double‐blind, placebo‐controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder
por: Inoue, Takeshi, et al.
Publicado: (2019)

The Efficacy of Vortioxetine on Anhedonia in Patients With Major Depressive Disorder
por: Cao, Bing, et al.
Publicado: (2019)

Efficacy of vortioxetine on the physical symptoms of major depressive disorder
por: Christensen, Michael Cronquist, et al.
Publicado: (2018)

Systematic Review and Meta-Analysis of Vortioxetine for the Treatment of Major Depressive Disorder in Adults
por: Zhang, Xinyan, et al.
Publicado: (2022)

Effect of vortioxetine versus venlafaxine on cognitive functions in adults with major depressive disorder: A randomized-controlled trial
por: Manna, Chayan K., et al.
Publicado: (2023)

Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder
por: Alvarez, Enric, et al.
Publicado: (2014)

Effects of Vortioxetine on Sleep Architecture of Adolescents with Major Depressive Disorder
por: Mlyncekova, Zuzana, et al.
Publicado: (2023)

Which Cognitive Domains are Improved by Treatment with Vortioxetine?
por: Harrison, John E, et al.
Publicado: (2016)

Vortioxetine improves cognition in mild cognitive impairment
por: Tan, Sheng Neng, et al.
Publicado: (2021)

The effect of vortioxetine on overall patient functioning in patients with major depressive disorder
por: Florea, Ioana, et al.
Publicado: (2017)

Gut Microbiota Changes in Patients With Major Depressive Disorder Treated With Vortioxetine
por: Ye, Xiaolin, et al.
Publicado: (2021)

Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials
por: Berhan, Asres, et al.
Publicado: (2014)

The efficacy and safety of 10 mg vortioxetine in the treatment of major depressive disorder: a meta-analysis of randomized controlled trials
por: Li, Guangjian, et al.
Publicado: (2016)

Vortioxetine for Cognitive Enhancement in Major Depression: From Animal Models to Clinical Research
por: Bennabi, Djamila, et al.
Publicado: (2019)

Improved cognitive function in patients with major depressive disorder after treatment with vortioxetine: A EEG study
por: Kim, Hong, et al.
Publicado: (2021)

A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder
por: Mahableshwarkar, Atul R, et al.
Publicado: (2015)

New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder
por: Katona, Cornelius L, et al.
Publicado: (2014)

Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature
por: Kelliny, Marc, et al.
Publicado: (2015)

The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis
por: Meeker, Amanda S, et al.
Publicado: (2015)

Effectiveness and Safety of Vortioxetine for the Treatment of Major Depressive Disorder in the Real World: A Systematic Review and Meta-Analysis
por: Li, Zejun, et al.
Publicado: (2023)

An Interim Analysis of a Randomized, Open-Label Study of Vilazodone, Escitalopram, or Vortioxetine for Major Depressive Disorder
por: Santi, N Simple, et al.
Publicado: (2023)

Cognitive impairment in post-covid-19 patients with major depressive episodes – a three-months study on the effect of vortioxetine
por: Di Nicola, M., et al.
Publicado: (2022)

Real-world effectiveness of vortioxetine in outpatients with major depressive disorder: functioning and dose effects
por: Papalexi, Eugenia, et al.
Publicado: (2022)

A 6-Month Open-Label Study of Vortioxetine among Cancer Patients with Major Depressive Disorder (MDD)
por: Ng, Chong Guan, et al.
Publicado: (2023)

Vortioxetine improves physical and cognitive symptoms in patients with post-COVID-19 major depressive episodes
por: Di Nicola, Marco, et al.
Publicado: (2023)

Vortioxetine Improves Depressive Symptoms and Cognition in Parkinson’s Disease Patients with Major Depression: An Open-Label Prospective Study
por: Santos García, Diego, et al.
Publicado: (2022)

Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: Results of the RECONNECT study
por: Christensen, Michael Cronquist, et al.
Publicado: (2022)

The efficacy and safety of 10 mg/day vortioxetine compared to placebo for adult major depressive disorder: a meta-analysis
por: Zheng, Jiahuan, et al.
Publicado: (2019)

A Feasibility Study of Patients with Major Depression and Substance Use Disorders: Vortioxetine as Maintenance Treatment
por: Basurte-Villamor, Ignacio, et al.
Publicado: (2022)

Vortioxetine vs. Other Antidepressants in Patients with Major Depressive Episode With or Without Substance Use Disorder
por: Kotzalidis, Georgios D., et al.
Publicado: (2021)

Vortioxetine Modulates the Regional Signal in First-Episode Drug-Free Major Depressive Disorder at Rest
por: Xiong, Shihong, et al.
Publicado: (2022)

A Subgroup Analysis of the Impact of Vortioxetine on Functional Capacity, as Measured by UPSA, in Patients with Major Depressive Disorder and Subjective Cognitive Dysfunction
por: Keefe, Richard S E, et al.
Publicado: (2018)

Major depression with musical obsession treated with vortioxetine: a case report
por: Yoshimura, Reiji, et al.
Publicado: (2021)

Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a “real-world” chart review study
por: De Berardis, Domenico, et al.
Publicado: (2020)

Effectiveness of Vortioxetine in Patients With Major Depressive Disorder in Real-World Clinical Practice: Results of the RELIEVE Study
por: Mattingly, Gregory W., et al.
Publicado: (2022)

A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults
por: McIntyre, Roger S., et al.
Publicado: (2014)

Emotional blunting and cognitive profile in elderly depressed patients in treatment with vortioxetine
por: Franza, F., et al.
Publicado: (2021)

Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 2-week, randomized, double-blind, placebo-controlled study
por: Vieta, Eduard, et al.
Publicado: (2019)

Practical Advice for Primary Care Clinicians on the Safe and Effective Use of Vortioxetine for Patients with Major Depressive Disorder (MDD)
por: Montano, C Brendan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_05b79adok9g3claksb8f209rr8